You are here
Iterative Therapeutics Inc.
UEI: NKKKLM6NKF39
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Enhanced NK cell activation via Fc receptor ligand cytokine combinations
Amount: $150,000.00Abstract Antibody dependent cellular cytotoxicity ADCC mediated by natural killer NK cells is a key effector function of therapeutic monoclonal antibodies mAb in use for treatment of establishe ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Rapid Response Vaccines for Botulinum Neurotoxins
Amount: $593,679.00DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are inc ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Novel HER2 targeting immunotherapeutics for breast cancer
Amount: $500,128.00DESCRIPTION (provided by applicant): Treatment of solid tumors with immunotherapy has met with limited success. One approach to tumor therapy has been to target tumors with anti-cancer monoclonal ant ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Vaccine enhancement through antigen targeting
Amount: $104,000.00DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immu ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Vaccine enhancement through antigen targeting
Amount: $104,000.00DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immu ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health
